As in any walk of life, if a business has developed a major step forward in technology, then it is critical to raise awareness of the improved performance across the target market.
In the medical world, one of the best ways of doing this is showcasing the breakthrough product/service at an industry conference, where key opinion leaders can ask questions and be further educated about the significant clinical and cost benefits.
Similarly, LungLife AI (LLAI) , a developer of next-generation early-stage lung cancer tests, said this morning that it would be formally presenting 2 abstract submissions (or scientific documents) regarding its flagship LungLB blood test at the Association for Molecular Pathology's (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada from 19th-23rd November, alongside also being included within the November 2024 issue of The Journal of Molecular Diagnostics.
CEO Paul Pagano commenting: "We are excited to have these two abstracts accepted for both presentation and publication by the AMP and believe this marks another important step in the pathway to commercialisation.
"AMP brings together a diverse community of physicians, scientists, and laboratory professionals from academic and community medical centres, government, and industry. We are looking forward to furthering discussions that allow us to demonstrate our commitment to advancing early detection of lung cancer and making a significant impact in this critical area of healthcare."
In terms of the numbers, house broker Investec has a 171p/share target price and is forecasting revenues to climb from $0.1m in FY24 to $0.5m and $1.2m over the next two years.
Follow News & Updates from LungLife AI: